-
FDA approves Altuviiio as once-weekly treatment for hemophilia A
25 Feb 2023 05:40 GMT
… Alnylam, Baxter Bioscience, Bayer, Biogen Idec, BioMarin, Bioverativ/Sanofi, … children and adults with hemophilia A.
The approval … Medicine, medical director at Hemophilia Center of Western Pennsylvania … for the treatment of hemophilia A.
Margaret V. …
-
Hemophilia Treatment Market Report 2022-2030: Growth Influencers Include Preference for Prophylactic Treatment, Rise in Diagnosis Rate, Significant Rise in Usage of Recombinant Coagulation Factor - ResearchAndMarkets.com
12 Dec 2022 12:26 GMT
… global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B … International Inc.
Baxalta
Bayer AG
Biogen Idec Inc.
Chugai Pharmaceutical Co.
CSL …
-
FDA approves Hemgenix as first gene therapy for treatment of hemophilia B
23 Nov 2022 01:24 GMT
… from Alnylam, Baxter Bioscience, Bayer, Biogen Idec, BioMarin, Bioverativ/Sanofi, Bristol … treatment option for patients with hemophilia B and represents important … associated with this form of hemophilia.”
Etranacogene dezaparvovec (Hemgenix, CSL …
-
Global Hemophilia Market to Reach $20.09 Billion by 2027 - ResearchAndMarkets.com
10 Aug 2022 15:53 GMT
… market was studied across Hemophilia A, Hemophilia B, and Hemophilia C.
Based on … Dynamics
Drivers
Increasing prevalence of hemophilia across the world
Rising promotions …
Baxter International, Inc.
Bayer AG
Biogen Idec, Inc.
BioMarin Pharmaceutical Inc
CSL …
-
Acquired Hemophilia Treatment Market Revenue to cross ~US$ 17.15 billion by 2030: Growth Plus Reports
05 Aug 2022 12:39 GMT
… ’ Geographically, the global acquired hemophilia treatment market is collective to … Moreover, continuous growth in acquired hemophilia incidences further fuels the growth … hemophilia treatment market are:
Pfizer Inc
Genentech Inc
CSL Ltd., Inc
Biogen Idec …
-
Biopharmaceuticals Market Comprehensive study by key players: Pfizer, Inc., F. Hoffmann-La Roche AG., Johnson & Johnson Services, Inc., Sanofi, Amgen Inc., AbbVie Inc., Merck & Co., Inc., Biogen Idec., Bayer AG., Eli Lilly and Company.
31 Oct 2019 01:44 GMT
… Inc., Merck & Co., Inc., Biogen Idec., Bayer AG., Eli Lilly and … divided into: Tumor, Diabetes, Cardiovascular, Hemophilia, Others
Regional Analysis For Biopharmaceuticals …
-
Global Hemophilia Market Research Report to 2027 - by Type, Therapy and Region - ResearchAndMarkets.com
01 Mar 2022 13:44 GMT
… suitable for entering the Global Hemophilia Market?
Market Dynamics
Drivers
… Increasing prevalence of hemophilia across the world
Rising promotions … Baxter International, Inc.
Bayer AG
Biogen Idec, Inc.
BioMarin Pharmaceutical Inc
CSL …
-
Hemophilia Market Research Report by Type, by Treatment, by Therapy, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
09 Feb 2022 02:35 GMT
… research report categorizes the Hemophilia to forecast the revenues … was studied across Hemophilia A, Hemophilia B, and Hemophilia C.
Based … Hemophilia Market, including AMBOSS, AmerisourceBergen Corporation, Baxter International, Inc., Bayer AG, Biogen Idec …
-
Hemophilia A Drug Market Size 2021 Global Industry Trends, Future Growth, Regional Overview, Market Share, Revenue, and Forecast Outlook till 2026, Says Industry Research Biz
15 Apr 2021 10:32 GMT
… ● Emergent BioSolutions
● Dimension Therapeutics
● Biogen Idec
● Catalyst Biosciences
● Inspiration Biopharmaceuticals
● … Retail Pharmacies
● Others
Global Hemophilia A Drug Market providing … helping analyze worldwide Global Hemophilia A Drug market …
-
Hemophilia Treatment Market Industry Research Report, Growth Trends and Competitive Analysis 2028
14 Jun 2020 19:54 GMT
… comprises of By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On … , Kedrion, Pfizer, Inc., Bayer AG, Biogen Idec, Inc., and Hospira, Inc.
Recent … .
Market Segmentation:
By Type
Hemophilia A
Hemophilia B
Hemophilia C
By Treatment
By …
About
© 1995-2025